Bausch Health Companies (TSE:BHC) has released an update.
Bausch Health Companies Inc. has successfully defended its patent for XIFAXAN (rifaximin) 550 mg as the U.S. Court of Appeals affirmed a decision preventing FDA approval of a generic version by Norwich Pharmaceuticals until October 2029. Despite this win, the court invalidated certain patents for the drug’s use in treating IBS-D, a point the company plans to contest while continuing to prioritize patient safety and access to the medication.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.
